Report: Comparison of Hepatitis C Treatment Costs

A report from IMS Institute for Healthcare Informatics shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan. Key facts in the report include: Of the seven countries analyzed, only Italy had a lower average net cost than...

Keep Reading

New Study: Negotiated Hepatitis C Prescription Drug Costs in United States Often Lower than in Price-Controlled European Countries and Japan

A new report, “Comparison of Hepatitis C Treatment Costs,” shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan. The report, conducted independently by IMS Institute for Healthcare Informatics and commissioned by the Pharmaceutical Care Management Association (PCMA),...

Keep Reading